The results showed that the IC50 values of (+)-PAH against CYP2A6, CYP2B6, and CYP2C19 were approximately three- to five-fold higher than those of (−)-form of PAH (Table 1). This evidence concerns the gene CYP2A6 and pulmonary arterial hypertension.